Kiniksa Pharmaceuticals International (KNSA) Receivables (2021 - 2026)

Kiniksa Pharmaceuticals International has reported Receivables for 6 years, with the latest figure at $23.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 42.03% year-over-year to $23.2 million; the trailing twelve-month figure through Mar 2026 stood at $23.2 million (down 42.03% YoY), and the FY2025 full-year result was $15.6 million, down 62.63% from the prior year.
• Receivables for Q1 2026 stood at $23.2 million, up from $15.6 million in the prior quarter.
• The five-year high for Receivables was $51.7 million in Q3 2025, with the low at $3.0 million in Q3 2023.
• Historically, Receivables has averaged $23.0 million across 5 years, with a median of $21.3 million in 2023.
• Annual changes were most pronounced in 2023 — Receivables tumbled 74.78% — and 2024, when it jumped 718.41%.
• Kiniksa Pharmaceuticals International's Receivables stood at $20.3 million in 2022, then advanced by 4.68% to $21.3 million in 2023, then soared by 96.2% to $41.7 million in 2024, then sank by 62.63% to $15.6 million in 2025, then soared by 48.93% to $23.2 million in 2026.
• The last three Receivables figures came in at $23.2 million (Q1 2026), $15.6 million (Q4 2025), and $51.7 million (Q3 2025), per Business Quant data.